Background: Transdermal patches are convenient to use, especially in Rotkreuz ZG Rotkreuz ZG patients with Alzheimer’s disease (AD)-associated dementia. However, various identified risks of errors in administering the patches cannot be disregarded. Patient Reminder Cards (PRCs, included a Medication record sheet [MRS]) have been recently introduced as a risk minimisation tool to prevent incorrect patch use (IU).

Objectives: This study aimed to assess the effectiveness of PRCs to prevent IU and to investigate the dose titration pattern of rivastigmine patches in a real-world setting.

Methods: This multinational, observational, 11-month study included patients with AD currently using rivastigmine patches (4.6 mg/day, 9.5 mg/day, 13.3 mg/day) accompanied by a caregiver. Study outcomes were IU, including multiple patch use (MPU), incorrect patch placement, other IUs, perceived usefulness of the PRCs, and titration patterns of the patches.

Results: Of the total 614 patients included, most were aged ≥ 65 years and had mild-to-moderate AD. Before and during the study, 27.7% and 18.0% of patients reported IU, respectively. Most patients used MRS, and 73.5% rated it ‘helpful’ and reported lower rates of IU than those who reported it ‘not helpful’ (13.9%-16.5% vs. 20.2%). Overall, 141 patients had dose titrations, with 75.8% being up-titrated from 4.6 mg/day to 9.5 mg/day after a mean duration of 58 days. Safety findings were consistent with the established profile for the rivastigmine patch.

Conclusion: PRC was effective as a risk minimisation tool in limiting the inappropriate use of rivastigmine patches. The majority of patients requiring dose-change were up-titrated to 9.5 mg/day patches.

背景：透皮贴剂使用方便，特别是在患有阿尔茨海默病 (AD) 相关痴呆症的 Rotkreuz ZG Rotkreuz ZG 患者中。但是，不能忽视补丁管理中各种已识别的错误风险。患者提醒卡（PRC，包括药物记录表 [MRS]）最近被用作风险最小化工具，以防止不正确的贴剂使用 (IU)。

目的：本研究旨在评估PRCs 预防IU 的有效性，并调查现实环境中利凡斯的明贴剂的剂量滴定模式。

方法：这项为期 11 个月的多国观察性研究纳入了目前使用利凡斯的明贴剂（4.6 毫克/天、9.5 毫克/天、13.3 毫克/天）的 AD 患者，并由一名护理人员陪同。研究结果是 IU，包括多次贴片使用 (MPU)、贴片放置不正确、其他 IU、PRC 的感知有用性和贴片的滴定模式。

结果：在纳入的 614 名患者中，大多数患者的年龄≥65 岁，并且患有轻度至中度 AD。在研究之前和研究期间，分别有 27.7% 和 18.0% 的患者报告了 IU。大多数患者使用 MRS，73.5% 的患者认为它“有帮助”并且报告的 IU 发生率低于那些报告“没有帮助”的患者（13.9%-16.5% 与 20.2%）。总体而言，141 名患者进行了剂量滴定，平均持续 58 天后，75.8% 的患者从 4.6 毫克/天增加到 9.5 毫克/天。安全性结果与卡巴拉汀贴剂的既定概况一致。

结论：PRC 是一种有效的风险最小化工具，可以限制利凡斯的明贴剂的不当使用。大多数需要改变剂量的患者被滴定至 9.5 毫克/天的贴剂。